Search - tctmd.com

Displaying 941 - 960 of 1503

Sort: Relevancy | Date

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

News Daily News

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

May 22, 2017

News Conference News EuroPCR 2017

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

Michael O'Riordan

May 18, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

Another Observational CTO Study Confirms Procedural Success of PCI but Doesn't Definitively Show Effect on Outcomes

News Daily News

Another Observational CTO Study Confirms Procedural Success of PCI but Doesn't Definitively Show Effect on Outcomes

Yael L. Maxwell

May 05, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

News Features

Stents as Essential Medicine: India’s Cap on Stent Prices Could Have Ripples Around the Globe

May 05, 2017

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

May 03, 2017

Who Should Get a Statin? Guidelines Don’t Match Up

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

The Left Main Debate: What Does it Mean for the Future of Intervention?

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

News Daily News

Younger, Heavier, and Uninsured: Trends Point to Rising Risks in Acute MI, Ischemic Stroke Patients

Yael L. Maxwell

April 11, 2017

Score May Ease Risk Stratification in Acute MI-Related Cardiogenic Shock

News Daily News

Score May Ease Risk Stratification in Acute MI-Related Cardiogenic Shock

April 10, 2017

Yo-Yo a No-No: Fluctuating Body Weight May Increase Morbidity and Mortality Among CAD Patients

News Daily News

Yo-Yo a No-No: Fluctuating Body Weight May Increase Morbidity and Mortality Among CAD Patients

April 06, 2017

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

News Daily News

Do NOACs Carry a Higher Risk of Acute MI? New Study Reopens Old Questions

March 28, 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

News Conference News ACC 2017

DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions

Yael L. Maxwell

March 19, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.